| Obstructive group | Non-obstructive group | ||||
| (%FEV1 ≤ 70%, n = 22) | (%FEV1 > 70%, n = 33) | ||||
| Clinical factors | Total | COPD | Smoker | Non-smoker | |
| (n = 55) | (C-group, n = 22) | (S-group, n = 10) | (N-group, n = 23) | ||
| Tiotropium | Tiotropium | Control | |||
| Age | Mean ± SD | 69.1 ± 7.8 | 74.2 ± 4.9 | 68.8 ± 6.3 | 64.4 ± 7.9 |
| range | 47 - 84 | 66 - 84 | 58 - 79 | 47 - 77 | |
| Gender | Male | 27 | 15 | 6 | 6 |
| Female | 28 | 7 | 4 | 17 | |
| Smoking history | Smoker | 16 | 6 | 10 | |
| Non-smoker | 39 | 16 | 23 | ||
| COPD (GOLD stages) | 0 | 21 | 6 | 15 | |
| 1 | 21 | 9 | 4 | 8 | |
| 2 | 13 | 13 | |||
| Histology | Adenocarcinoma | 42 | 16 | 5 | 21 |
| Squamous cell carcinoma | 12 | 6 | 5 | 1 | |
| Large cell carcinoma | 1 | 1 | |||
| Operative procedure | Lobectomy | 53 | 22 | 8 | 23 |
| Bilobectomy | 2 | 2 | |||
| Lobectomy site | Right side | 33 | 14 | 6 | 13 |
| Upper lobe | 13 | 6 | 2 | 5 | |
| Upper-middle lobe | 1 | 1 | |||
| Middle lobe | 3 | 3 | |||
| Middle-lower lobe | 1 | 1 | |||
| Lower lobe | 15 | 8 | 2 | 5 | |
| Left side | 22 | 8 | 4 | 10 | |
| Upper lobe | 14 | 5 | 2 | 7 | |
| Lower lobe | 8 | 3 | 2 | 3 | |
| Pathological stage | IA | 32 | 12 | 5 | 15 |
| IB | 9 | 4 | 2 | 3 | |
| IIA | |||||
| IIB | 4 | 2 | 1 | 1 | |
| IIIA | 8 | 4 | 2 | 2 | |
| IIIB | 1 | 1 | |||
| IV | 1 | 1 | |||